The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 9 of 23

Stories

  1. Apnimed posts results of Phase 3 AD109 trial in obstructive sleep apnea

    The study, enrolling 660 participants, compared AD109 to placebo over 1 year and was completed with primary data posted on November 3, 2026. It began on August 28, 2023 and reached primary completion on May 7, 2025.

  2. Johnson & Johnson Consumer posts results of Phase 3 dental pain study

    The study, completed in May 2024, enrolled 447 participants and compared a fixed combination of acetaminophen/naproxen sodium with acetaminophen, naproxen sodium, and placebo for postoperative dental pain. Results were first posted on ClinicalTrials.gov on November 3, 2026.

  3. Povorcitinib meets primary endpoint in two phase 3 vitiligo trials

    The authors reported that povorcitinib 30 mg daily achieved ≥75% improvement in facial Vitiligo Area Scoring Index at week 52 in both STOP-V1 and STOP-V2, with 18.9% versus 6.8% and 18.9% versus 3.1% respectively. Treatment-emergent adverse events were similar to placebo, with 68.7%/66.7% versus 63.7%/62.7% and no class-specific serious events.

  4. Semaglutide 2.4 mg scored 7.3 points above placebo on KCCQ-CSS in HFpEF with type 2 diabetes

    In a 617-participant trial, the KCCQ-CSS difference between semaglutide 2.4 mg and placebo was 7.3 points at week 52, the Novo Nordisk record shows. The record now holds results for a completed trial in obesity-related heart failure with preserved ejection fraction and type 2 diabetes.

  5. Specific Biologics announces oversubscribed US$35 million Series A financing

    Specific Biologics announced the closing of an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners, with participation from Lumira Ventures, adMare BioInnovations and other investors. The proceeds will be used to advance the lead Dualase therapeutic candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II clinical trial in patients with C9ORF72-associated ALS.

  6. New Phase 3 trials registered, week of November 2, 2026: 17 industry trials

    Industry sponsors registered 17 Phase 3 trials on ClinicalTrials.gov in the week of November 2 to 8, 2026. They plan to enroll 40,993 participants in all; the largest, Guangzhou Patronus Biotech's LYB005 trial, plans to enroll 25,000.

  7. Keymed registers Phase 3 trial of CM336+CM313 in relapsed multiple myeloma

    The study, led by Keymed Biosciences Co.Ltd, plans to enroll 320 participants and start in December 2026. It compares CM336+CM313 with Daratumumab+Pomalidomide+Dexamethasone in patients who have received 1 to 3 prior lines of therapy.

  8. Merck registers Phase 3 trial of Gocatamig with Durvalumab in small cell lung cancer

    Merck Sharp & Dohme LLC has registered a Phase 3 randomized study to evaluate the safety and efficacy of Gocatamig (MK-6070) with Durvalumab versus Durvalumab alone as consolidation therapy in limited-stage small cell lung cancer. The trial plans to enroll 564 participants and is expected to start on December 7, 2026.

  9. Guangzhou Patronus registers Phase III trial of LYB005 RSV vaccine in older adults

    The Guangzhou Patronus Biotech Co., Ltd. study plans to enroll an estimate of 25000 participants aged 60 years and older, with a planned start date of November 2026 and a planned primary completion date of September 2027. The trial is randomized, observer-blind, and placebo-controlled.

  10. Novo Nordisk posts results of Phase 3 semaglutide trial in HFpEF with diabetes

    The company posted results of a completed Phase 3 study that enrolled 617 participants with heart failure with preserved ejection fraction and type 2 diabetes, comparing semaglutide 2.4 mg once-weekly to a dummy medicine. The trial began on June 15 2021 and reached primary completion on October 11 2023.

  11. Abbott, COPD, and AbbVie: the issue of October 26, 2026

    The week of October 26 to November 1, 2026: 47 briefs, 7 stories, led by Abbott, COPD, and AbbVie.

  12. Abbott reports strong 30-day outcomes in TECTONIC IVL study

    The TECTONIC CAD IVL IDE Study enrolled 335 patients and met its primary safety endpoint with a 30-day target lesion failure rate of 0.3%. The study also achieved a primary effectiveness endpoint with procedural success in 97% of patients.